278 related articles for article (PubMed ID: 25253952)
1. Eltrombopag in chronic hepatitis C.
Mihăilă RG; Cipăian RC
World J Gastroenterol; 2014 Sep; 20(35):12517-21. PubMed ID: 25253952
[TBL] [Abstract][Full Text] [Related]
2. Eltrombopag in patients with chronic liver disease.
Giannini EG; Afdhal NH
Expert Opin Pharmacother; 2013 Apr; 14(5):669-78. PubMed ID: 23452139
[TBL] [Abstract][Full Text] [Related]
3. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.
Afdhal NH; Dusheiko GM; Giannini EG; Chen PJ; Han KH; Mohsin A; Rodriguez-Torres M; Rugina S; Bakulin I; Lawitz E; Shiffman ML; Tayyab GU; Poordad F; Kamel YM; Brainsky A; Geib J; Vasey SY; Patwardhan R; Campbell FM; Theodore D
Gastroenterology; 2014 Feb; 146(2):442-52.e1. PubMed ID: 24126097
[TBL] [Abstract][Full Text] [Related]
4. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.
McHutchison JG; Dusheiko G; Shiffman ML; Rodriguez-Torres M; Sigal S; Bourliere M; Berg T; Gordon SC; Campbell FM; Theodore D; Blackman N; Jenkins J; Afdhal NH;
N Engl J Med; 2007 Nov; 357(22):2227-36. PubMed ID: 18046027
[TBL] [Abstract][Full Text] [Related]
5. Molecule of the month. Eltrombopag.
Drug News Perspect; 2008; 21(6):344. PubMed ID: 18836592
[No Abstract] [Full Text] [Related]
6. Efficacy and safety of eltrombopag in Japanese patients with chronic liver disease and thrombocytopenia: a randomized, open-label, phase II study.
Kawaguchi T; Komori A; Seike M; Fujiyama S; Watanabe H; Tanaka M; Sakisaka S; Nakamuta M; Sasaki Y; Oketani M; Hattori T; Katsura K; Sata M
J Gastroenterol; 2012 Dec; 47(12):1342-51. PubMed ID: 22674141
[TBL] [Abstract][Full Text] [Related]
7. Modeling and simulation support eltrombopag dosing in thrombocytopenic patients with chronic HCV infection.
Zhang J; Thapar M; Farrell C; Wire MB
Pharm Res; 2015 Jun; 32(6):2015-28. PubMed ID: 25534682
[TBL] [Abstract][Full Text] [Related]
8. Potential usefulness of thrombopoietin receptor agonists in haemophiliacs with thrombocytopaenia due to chronic liver disease.
Aguilar C
Blood Coagul Fibrinolysis; 2013 Apr; 24(3):231-6. PubMed ID: 23518832
[TBL] [Abstract][Full Text] [Related]
9. Miniaturized 3D bone marrow tissue model to assess response to Thrombopoietin-receptor agonists in patients.
Di Buduo CA; Laurent PA; Zaninetti C; Lordier L; Soprano PM; Ntai A; Barozzi S; La Spada A; Biunno I; Raslova H; Bussel JB; Kaplan DL; Balduini CL; Pecci A; Balduini A
Elife; 2021 Jun; 10():. PubMed ID: 34059198
[TBL] [Abstract][Full Text] [Related]
10. Eltrombopag: a review of its use in the treatment of thrombocytopenia in patients with chronic hepatitis C.
Burness CB
Drugs; 2014 Oct; 74(16):1961-1971. PubMed ID: 25331767
[TBL] [Abstract][Full Text] [Related]
11. Eltrombopag (Revolade ) and thrombocytopenia in patients with hepatitis C. Hepatotoxic drug; more harms than benefits.
Prescrire Int; 2015 Sep; 24(163):208-9. PubMed ID: 26417629
[TBL] [Abstract][Full Text] [Related]
12. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist.
Jenkins JM; Williams D; Deng Y; Uhl J; Kitchen V; Collins D; Erickson-Miller CL
Blood; 2007 Jun; 109(11):4739-41. PubMed ID: 17327409
[TBL] [Abstract][Full Text] [Related]
13. Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: systematic review and meta-analysis of randomized controlled trials.
Catalá-López F; Corrales I; Martín-Serrano G; Tobías A; Calvo G
Med Clin (Barc); 2012 Oct; 139(10):421-9. PubMed ID: 22266082
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
Platzbecker U; Wong RS; Verma A; Abboud C; Araujo S; Chiou TJ; Feigert J; Yeh SP; Götze K; Gorin NC; Greenberg P; Kambhampati S; Kim YJ; Lee JH; Lyons R; Ruggeri M; Santini V; Cheng G; Jang JH; Chen CY; Johnson B; Bennett J; Mannino F; Kamel YM; Stone N; Dougherty S; Chan G; Giagounidis A
Lancet Haematol; 2015 Oct; 2(10):e417-26. PubMed ID: 26686043
[TBL] [Abstract][Full Text] [Related]
15. Eltrombopag for thrombocytopenic patients with hepatitis C virus infection and cirrhosis.
Ji F; Deng H; Li Z
Gastroenterology; 2014 Jul; 147(1):253-4. PubMed ID: 24877867
[No Abstract] [Full Text] [Related]
16. [Eltrombopag for the treatment of thrombocytopenia in patients with chronic hepatitis C: two case reports].
Guglieri-López B; Ventura-Cerdá JM; Carmena-Carmena J; Climente-Mónica M
Farm Hosp; 2013; 37(5):419-21. PubMed ID: 24128106
[No Abstract] [Full Text] [Related]
17. Eltrombopag: a review of its use in treatment-refractory chronic primary immune thrombocytopenia.
Garnock-Jones KP
Drugs; 2011 Jul; 71(10):1333-53. PubMed ID: 21770480
[TBL] [Abstract][Full Text] [Related]
18. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.
Mittelman M; Platzbecker U; Afanasyev B; Grosicki S; Wong RSM; Anagnostopoulos A; Brenner B; Denzlinger C; Rossi G; Nagler A; Garcia-Delgado R; Portella MSO; Zhu Z; Selleslag D
Lancet Haematol; 2018 Jan; 5(1):e34-e43. PubMed ID: 29241762
[TBL] [Abstract][Full Text] [Related]
19. A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine.
Svensson T; Chowdhury O; Garelius H; Lorenz F; Saft L; Jacobsen SE; Hellström-Lindberg E; Cherif H
Eur J Haematol; 2014 Nov; 93(5):439-45. PubMed ID: 24853277
[TBL] [Abstract][Full Text] [Related]
20. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
Grainger JD; Locatelli F; Chotsampancharoen T; Donyush E; Pongtanakul B; Komvilaisak P; Sosothikul D; Drelichman G; Sirachainan N; Holzhauer S; Lebedev V; Lemons R; Pospisilova D; Ramenghi U; Bussel JB; Bakshi KK; Iyengar M; Chan GW; Chagin KD; Theodore D; Marcello LM; Bailey CK
Lancet; 2015 Oct; 386(10004):1649-58. PubMed ID: 26231455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
